| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 02/19/2004 | CA2494252A1 Psmcs as modifiers of the rb pathway and methods of use |
| 02/19/2004 | CA2493297A1 Methods to reprogram splice site selection in pre-messenger rnas |
| 02/19/2004 | CA2489301A1 Vaccinia virus host range genes to increase the titer of avipoxviruses |
| 02/18/2004 | EP1389306A2 Method for detecting progredient chronic dementia, and corresponding peptides and detection reagents |
| 02/18/2004 | EP1389237A2 Novel fibroblast growth factors |
| 02/18/2004 | EP1389236A2 Immunoglobulin superfamily variants expressed in mesenchymal cells and therapeutic uses thereof |
| 02/18/2004 | EP1389182A1 Complexes for transferring substances of interest into a cell |
| 02/18/2004 | EP1389130A2 Use of osteopontin for the treatment and/or prevention of neurologic diseases |
| 02/18/2004 | EP1389043A1 Foot and mouth disease virus vaccine |
| 02/18/2004 | EP0817851B1 Dna encoding human papilloma virus type 18 |
| 02/18/2004 | EP0791064B1 Method for enhancing the immunogenicity of an immunogenic compound or hapten, and use thereof for preparing vaccines |
| 02/18/2004 | EP0734264B1 Compositions that specifically bind to colorectal cancer cells and methods of using the same |
| 02/18/2004 | CN1476483A Modified vaccinia ankara virus variant |
| 02/18/2004 | CN1476479A Human protooncogene and protein encoded therein |
| 02/18/2004 | CN1476478A Human cervical cancer 2 protooncogene and protein encoded therein |
| 02/18/2004 | CN1475571A Expression of recombination SARS virus gene in pleiomorphic Hansen yeast and its use |
| 02/18/2004 | CN1475277A Method of gauze window type rectifying accelerating gene microsphere and gene gun |
| 02/18/2004 | CN1138563C Vector for diagnosis and treatment of solid tumors including melanoma |
| 02/18/2004 | CN1138533C Liposomes |
| 02/17/2004 | WO2004076645A3 Compositions and methods for cytomegalovirus treatment |
| 02/17/2004 | US6693186 Neisseria meningitidis polypeptide, nucleic acid sequence and uses thereof |
| 02/17/2004 | US6693167 Peptide-based gemini compounds |
| 02/17/2004 | US6693130 Inhibitors of epoxide hydrolases for the treatment of hypertension |
| 02/17/2004 | US6693086 Eliciting nonantigen and strong antigen specific immune response; cancer, allergic inflammation and/or infectious disease prevention |
| 02/17/2004 | US6693077 Keratinocyte growth factor-2 |
| 02/17/2004 | US6692966 Packaging systems for human recombinant adenovirus to be used in gene therapy |
| 02/17/2004 | US6692964 Stimulating proliferating cell prior to introducing nucleic acid molecule |
| 02/17/2004 | US6692959 Hybrid nucleic acids; prevent, controlling gene expression; antiinflammatory agents |
| 02/17/2004 | US6692956 Recombinant adenoviral vectors |
| 02/17/2004 | US6692943 Persephin and related growth factors |
| 02/17/2004 | US6692938 Peptide for use in the treatment of inflammation, arthritis, glomerulonephritis, asthma, psoriasis, viral infections, cancer, atherosclerosis, leukemia and autoimmune diseases |
| 02/17/2004 | US6692936 Novel polypeptide belonging to the class of proteins known as g-protein coupled receptors |
| 02/17/2004 | US6692911 Cell delivery compositions |
| 02/17/2004 | US6692750 Introducing into cells recombinant alphavirus rna genome and helper rna encoding alphavirus structural proteins, including coding sequences for proteins and cis acting replication signals; incubating to produce infectious virus particles |
| 02/17/2004 | US6692744 Betaglycan as an inhibin receptor and uses thereof |
| 02/17/2004 | US6692741 Treatment of acute lung injury and fibrosis with antagonists of β6-specific antibodies |
| 02/17/2004 | US6692738 Implanting cell-matrix structure comprising matrix having attached thereto an effective amount of cells stably expressing a gene encoding biological modifier to stop or regress the excessive tissue proliferation |
| 02/17/2004 | US6692737 In vivo protein production and delivery system for gene therapy |
| 02/17/2004 | US6692736 Replication-competent adenovirus vector including two genes co-transcribed as single mrna under transcriptional control of heterologous target cell-specific transcriptional regulatory element; one has mutation or deletion of endogenous promoter |
| 02/12/2004 | WO2004013629A2 Screening for agents suitable for treatment of leukocyte associated inflammatory diseases |
| 02/12/2004 | WO2004013356A1 Compositions, methods, and kits relating to behab and primary cns tumors |
| 02/12/2004 | WO2004013355A1 Sirna-mediated gene silencing with viral vectors |
| 02/12/2004 | WO2004013330A1 Multifunctional genetic constructions having a high capacity to inhibit the expression of ccr5 on the cell surface |
| 02/12/2004 | WO2004013317A1 A method of obtaining a bacteriophage strain of increased affinity to eukaryotic cells, preparations containing it, and applications of bacteriophages |
| 02/12/2004 | WO2004013313A2 Antisense nucleic acids |
| 02/12/2004 | WO2004013310A2 Methods of down regulating target gene expression in vivo by introduction of interfering rna |
| 02/12/2004 | WO2004013309A2 PAPSSs AS MODIFIERS OF THE AXIN PATHWAY AND METHODS OF USE |
| 02/12/2004 | WO2004013308A2 Maxs as modifiers of the axin pathway and methods of use |
| 02/12/2004 | WO2004013280A2 ALLELE-SPECIFIC siRNA-MEDIATED GENE SILENCING |
| 02/12/2004 | WO2004013279A2 Helix-hairpin-helix motifs to manipulate properties of dna processing enzymes |
| 02/12/2004 | WO2004013182A1 Hyaluronic acid derivatives |
| 02/12/2004 | WO2004013174A1 Use of disease-associated gene |
| 02/12/2004 | WO2004012775A2 Bicistronic vector encoding a vegf and an fgf, use thereof |
| 02/12/2004 | WO2004012732A2 Use of a proteasome inhibitor in the treatment of endothelial dysfunction and/or in a low-dose proteasome inhibitor therapy |
| 02/12/2004 | WO2004012504A1 Miglur5 metabotropic glutamate receptor gene disruptions, and com positions and methods related thereto |
| 02/12/2004 | WO2003094963A3 Methylated immunostimulatory oligonucleotides and methods of using the same |
| 02/12/2004 | WO2003087832A3 Diagnosis of carcinoma using raigi polypeptides |
| 02/12/2004 | WO2003070968A3 RNA INTERFERENCE MEDIATED INHIBITION OF GASTRIC INHIBITORY POLYPEPTIDE (GIP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 02/12/2004 | WO2003065994A3 Schwann cell and phosphodiesterase inhibitors based therapy |
| 02/12/2004 | WO2003060142A3 Compositions and methods for controlled release |
| 02/12/2004 | WO2003056022B1 Method for producing a transgenic organism using a lentiviral expression vector such as eiav |
| 02/12/2004 | WO2003050301A3 Susceptibility locus for schizophrenia |
| 02/12/2004 | WO2003050262A3 Method for the generation of antigen-specific lymphocytes |
| 02/12/2004 | WO2003050249A3 Islet cells from human embryonic stem cells |
| 02/12/2004 | WO2003047684A3 Method for intracellular modifications within living cells using pulsed electric fields |
| 02/12/2004 | WO2003044524A3 Methods and means for influencing intracellular communication and intracellular organelle transport |
| 02/12/2004 | WO2003044203A3 Homologous recombination vector, preparations and uses |
| 02/12/2004 | WO2003039404A3 Methods for treating ocular neovascular diseases |
| 02/12/2004 | WO2003039346A3 Diagnostics and therapeutics for ocular abnormalities |
| 02/12/2004 | WO2003035012A3 Mutant purine nucleoside phosphorylase proteins and cellular delivery thereof |
| 02/12/2004 | WO2002101357A9 Molecular signatures of commonly fatal carcinomas |
| 02/12/2004 | WO2002101057A8 Gene transfer into primate embryonic stem cells using vsv-g pseudo type simian immunodeficiency virus vector |
| 02/12/2004 | WO2002076507A3 Uses of opg ligand to modulate immune responses |
| 02/12/2004 | WO2002066647A3 Type 2 ctokine receptor and nucleic acids encoding same |
| 02/12/2004 | WO2002059609A3 Methods of diagnosing colorectal cancer and/or breast cancer, compositions, and methods of screening for colorectal cancer and/or breast cancer modulators |
| 02/12/2004 | WO2002035981A3 Methods and compositions for the treatment of human immunodeficiency virus infection |
| 02/12/2004 | US20040031067 Compositions and methods for preparing vascularized dermal reconstructs, vascularized skin grafts, and for enhancing vascularization in situ in response to a variety of medical conditions |
| 02/12/2004 | US20040030117 Attenuating mutations and methods of making them, the alphavirus vector delivers the heterologous nucleotide sequence to the cells of the bone, bone marrow, and/or bone-associated connective tissue |
| 02/12/2004 | US20040030115 Nucleic acids containing the coding regions of the genes encoding such proteins, vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins; useful for diagnosing and treating disorders related to them |
| 02/12/2004 | US20040030114 Myostatin regulatory region, nucleotide sequence determination and methods for its use |
| 02/12/2004 | US20040030111 Used in directing the misfolding of functional RNA molecules that are characterized by secondary and/or tertiary folding to achieve an active conformation, whereby the misfolding modifies the activity of the RNA molecules |
| 02/12/2004 | US20040030099 Regulation of human patched-like protein |
| 02/12/2004 | US20040029825 Methods of minimizing immunological rejection of a nuclear transfer fetus |
| 02/12/2004 | US20040029795 Gene which modulate gene expression of protein |
| 02/12/2004 | US20040029793 Genetic engineering; antibodies; antiinflammatory agents, circulation diseases, anticancer agents, antidiabetic agents, gastrointestinal disorders |
| 02/12/2004 | US20040029775 Methods and compounds for influencing beta3-integrin-dependent intracellular processes |
| 02/12/2004 | US20040029751 Preparatiom for douches and/or irrigations of natural or pathological cavities in the human body |
| 02/12/2004 | US20040029281 Carrier vectors through an epithelium with tight junctions |
| 02/12/2004 | US20040029280 Viral vectors with modified tropism |
| 02/12/2004 | US20040029279 The packaging systems are based on the expression of split-helper functions by coinfecting cells with recombinant vectors, such as recombinant poxvirus vectors |
| 02/12/2004 | US20040029278 Recombinant alphaviruses which are capable of expressing a heterologous sequence in target cells |
| 02/12/2004 | US20040029275 Short interfering RNA (siRNAs); reducing expression by obtaining and introducing into a cell multiple single or double stranded RNAs (dsRNAs) or DNA constructs capable of expressing multiple siRNAs in cells |
| 02/12/2004 | US20040029247 Regulation of human adenylate cyclase, type iv |
| 02/12/2004 | US20040029227 Prolonging expression of an exogenous gene in a cell transduced with the gene; for treatment of brain disorders like tumours, Alzheimer's disease, Parkinson's disease, lateral amyotrophic sclerosis, neurodegenerative disorders |
| 02/12/2004 | US20040029199 Human cervical cancer 2 protooncogene and protein encoded therein |
| 02/12/2004 | US20040029160 A triplex comprising a hairpin having polypyrimidine sequence linked to a complementary polypurine; targeting single-stranded oligonucleotides and DNA using the hairpins and triplexes |
| 02/12/2004 | US20040029158 HOP - a novel cardiac-restricted transcriptional factor potentially useful for cardiac regeneration and specification |
| 02/12/2004 | US20040029150 Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| 02/12/2004 | US20040029148 Nucleic acid constructs and cells, and methods utilizing same for modifying the electrophysiological function of excitable tissues |
| 02/12/2004 | US20040029147 Mutations in the ferroportin 1 gene associated with hereditary haemochromatosis |